BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 25004111)

  • 1. Expression of Th1, Th2, lymphocyte trafficking and activation markers on CD4+ T-cells of Hymenoptera allergic subjects and after venom immunotherapy.
    Cabrera CM; Urra JM; Alfaya T; Roca Fde L; Feo-Brito F
    Mol Immunol; 2014 Nov; 62(1):178-85. PubMed ID: 25004111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.
    Bellinghausen I; Metz G; Enk AH; Christmann S; Knop J; Saloga J
    Eur J Immunol; 1997 May; 27(5):1131-9. PubMed ID: 9174602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 serum levels and response to hymenoptera venom immunotherapy.
    Foschi FG; Emiliani F; Savini S; Quercia O; Stefanini GF
    J Investig Allergol Clin Immunol; 2008; 18(4):279-83. PubMed ID: 18714536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agreement of skin test with IL-4 production and CD40L expression by T cells upon immunotherapy of subjects with systemic reactions to Hymenoptera stings.
    Urra JM; Cabrera CM; Alfaya T; Feo-Brito F
    Mol Immunol; 2016 Feb; 70():134-9. PubMed ID: 26774053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy.
    Bellinghausen I; Klostermann B; Böttcher I; Knop J; Saloga J
    Immunology; 2004 May; 112(1):80-6. PubMed ID: 15096187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venom immunotherapy in patients with allergic reactions to insect stings.
    Incorvaia C; Mauro M; Gritti BL; Makri E; Ridolo E
    Expert Rev Clin Immunol; 2018 Jan; 14(1):53-59. PubMed ID: 29202591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
    Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
    Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basophil sensitivity in patients not responding to venom immunotherapy.
    Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
    Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Hymenoptera venom allergy: an update.
    Pesek RD; Lockey RF
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):340-6. PubMed ID: 24887986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When can immunotherapy for insect sting allergy be stopped?
    Müller UR; Ring J
    J Allergy Clin Immunol Pract; 2015; 3(3):324-8; quiz 329-30. PubMed ID: 25956311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hymenoptera venom immunotherapy and field stings.
    Lang R; Hawranek T
    J Investig Allergol Clin Immunol; 2006; 16(4):224-31. PubMed ID: 16889279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy.
    Siegmund R; Vogelsang H; Machnik A; Herrmann D
    J Allergy Clin Immunol; 2000 Dec; 106(6):1190-5. PubMed ID: 11112905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CD63 expression as marker of in vitro basophil activation in identifying the culprit in insect venom allergy.
    Eberlein-König B; Rakoski J; Behrendt H; Ring J
    J Investig Allergol Clin Immunol; 2004; 14(1):10-6. PubMed ID: 15160437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects.
    Arzt L; Bokanovic D; Schrautzer C; Laipold K; Möbs C; Pfützner W; Herzog SA; Vollmann J; Reider N; Bohle B; Aberer W; Sturm GJ
    Allergy; 2018 Jun; 73(6):1223-1231. PubMed ID: 29171032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
    White KM; England RW
    Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study.
    Sturm GJ; Böhm E; Trummer M; Weiglhofer I; Heinemann A; Aberer W
    Allergy; 2004 Oct; 59(10):1110-7. PubMed ID: 15355471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of hypersensitivity to hymenoptera venom.
    Roers A; Hunzelmann N
    Expert Opin Biol Ther; 2005 Oct; 5(10):1349-58. PubMed ID: 16197340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key Issues in Hymenoptera Venom Allergy: An Update.
    Alfaya Arias T; Soriano Gómis V; Soto Mera T; Vega Castro A; Vega Gutiérrez JM; Alonso Llamazares A; Antolín Amérigo D; Carballada Gonzalez FJ; Dominguez Noche C; Gutierrez Fernandez D; Marques Amat L; Martinez Arcediano A; Martinez San Ireneo M; Moreno Ancillo A; Puente Crespo Y; Ruiz Leon B; Sánchez Morillas L;
    J Investig Allergol Clin Immunol; 2017; 27(1):19-31. PubMed ID: 28211342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.